Abstract：Objective: To analysis of clinical value of plasma cardiotrophin -1(CT-1), growth hormone releasing polypeptide (Ghrelin), lipoprotein-associated phospholipase A2(Lp-PLA2) in coronary heart disease. Methods: 176 cases of coronary heart disease was from March 2015 to June 2018, 43 cases of control group, 45 stable angina pectoris (SAP), 42 cases of unstable angina pectoris (UAP), 46 cases of acute myocardial infarction (AMI). Comparison between groups of plasma CT-1, Ghrelin, Lp-PLA2 level, left ventricular ejection fraction (LVEF), left ventricular end systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV),and analyze the correlation between them, and the relationship between cardiac adverse events. Results: plasma CT-1,Lp-PLA2 levels, LVEDV and LVESV of AMI group was higher than the UAP group, SAP group, control group, plasma Ghrelin of AMI group was lower than the UAP group, SAP group, control group, there was statistically significant differences (P<0.05). Plasma CT, Lp-PLA2 level and LVEF was negatively correlated, (r=-0.786, -0.654, P<0.05), and both LVEDV and LVESV was positively correlated, (r=0.881, 0.702, 0.621, 0.514, P<0.05). plasma Ghrelin level and LVEF was positively correlated (r=0.620, P<0.05), and LVEDV, LVESV were negatively correlated, (r=-0.433, 0.-594, P<0.05). Plasma CT-1 and Lp-PLA2 levels in MACE group were higher than those in non-MACE group, and plasma Ghrelin was lower than that in non-MACE group (P<0.05). The areas under the curve predicted by CT-1, Ghrelin, Lp-PLA2, CT-1+Ghrelin +Lp-PLA2 for MACE were 0.816, 0.797 and 0.699, and the areas under the curve of CT-1+Ghrelin +Lp-PLA2 were larger than a single index. Multifactorial Logistic regression analysis shows, plasma levels of CT-1 and Lp-PLA2 was independent risk factors for adverse cardiac events in patients with coronary heart disease, Ghrelin was a protective factor. Conclusion: Plasma CT-1, Ghrelin, Lp-PLA2 are related to coronary heart disease, and their changes may indicate adverse cardiovascular events.
[1] 郑志君,王晓蕊,苗昌荣,等.冠心病患者血浆心肌营养素-1、胃饥饿素、脂蛋白相关磷脂酶A2水平与心功能的关系[J].中国心血管病研究,2018,16(10):904~907. [2] 杨毅宁.冠心病新型生物标志物的研究进展[J].新疆医科大学学报,2019,42(6):27~29. [3] 王蔚文.临床疾病诊断与疗效判断标准[M].科技技术文献出版社,2010.184~186. [4] Hohmann C, Pfister R, Michels G. Different symptoms and course of coronary heart disease in men and women[J]. Dtsch Med Wochenschr,2017,142(21):1578~1584. [5] 霍勇.冠心病诊治2017年度盘点[J].浙江医学,2018,40(5):421~424. [6] 褚爱娟,楼亚玲,翁丹丹.冠心病患者幽门螺杆菌感染与血清Ghrelin、同型半胱氨酸水平的相关性研究[J].中国微生态学杂志,2016,28(3):309~311. [7] Lilleness B M, Frishman W H. Ghrelin and the cardiovascular system.[J]. Cardiology in Review, 2016, 24(6):288~297. [8] Celik O, Demirci E, Aydin M, et al. Evaluation of ghrelin levels and endothelial functions in patients with coronary slow flow phenomenon[J]. Interventional Medicine & Applied Science,2017, 9(3):154~159. [9] Younus A, Humayun C, Ahmad R, et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review[J].Clin Lipidol,2017,11(2):328~337. [10] 李娟红,赵子贤,吴德彬,等.SF和Lp-PLA2水平与冠心病的相关性研究[J].检验医学与临床,2017,14(6):765~767. [11] 彭然,彭佳,李向平.超声心动图在冠心病评价中的应用和进展[J].心血管病学进展,2018,39(5):55~59. [12] 谭祥地,林嘉隆.血浆脂蛋白相关性磷脂酶A2水平在冠心病患者诊断中的价值[J].心肺血管病杂志,2017,36(6):454~457.
2019, Vol. 25 
冀公网安备13080202000786号